Global Markets for Treatments of Dementia and Movement Disorders - Focus on Movement Disorders

Published by: BCC Research

Published: Sep. 1, 2012 - 197 Pages

Table of Contents

CHAPTER 1 INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC RESEARCH REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS)

SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS)

CHAPTER 3 OVERVIEW

THE BRAIN

CEREBRAL CORTEX

BRAIN STEM

SPINAL CORD

NEUROTRANSMITTERS

CLASSIFICATION OF NEURODEGENERATIVE DISORDERS

TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE

NEURODEGENERATIVE DISORDERS

ALZHEIMER'S DISEASE

LEWY BODY DEMENTIA

PICK'S DISEASE

HUNTINGTON'S DISEASE

CORTICAL BASAL GANGLIONIC DEGENERATION

PARKINSON'S DISEASE

MULTIPLE SYSTEM ATROPHY

PROGRESSIVE SUPRANUCLEAR PALSY

HALLERVORDEN-SPATZ DISEASE

DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS

DIAGNOSTIC TESTS FOR PARKINSON'S

DIAGNOSTIC TESTS FOR ALZHEIMER'S

DIAGNOSTIC TESTS FOR PICK'S DISEASE

DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY

DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY

DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION

DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA

DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE

CHAPTER 4 REGULATORY ASPECTS

INTRODUCTION

DRUG APPROVALS

TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012

TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS

TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012

TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012

REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND MOVEMENT DISORDER PRODUCTS

CHAPTER 5 NEW DEVELOPMENTS

TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2012

TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2011

TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010

CHAPTER 6 GLOBAL MARKETS

MARKETS BY CLINICAL/PATHOLOGICAL FEATURE

MARKET OVERVIEW

MARKET REVENUES

TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)

FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)

MARKET BY DISEASE TYPE

MARKET OVERVIEW

MARKET REVENUES

TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%)

FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%)

MARKET BY REGION

MARKET OVERVIEW

MARKET REVENUE

TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)

FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)

MARKETS BY TECHNOLOGY

MARKET OVERVIEW

MARKET REVENUE

TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS)

FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)

FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)

CHAPTER 7 MARKET FOR MOVEMENT DISORDER SYNDROMES

MARKET BY TYPE OF DISEASE

PARKINSON'S DISEASE

MULTIPLE SYSTEM ATROPHY

PROGRESSIVE SUPRANUCLEAR PALSY

HALLERVORDEN-SPATZ DISEASE

MARKET OVERVIEW

TABLE 17 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, THROUGH 2017 ($ MILLIONS)

FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 18 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)

FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)

MARKETS BY REGION

MARKET OVERVIEW

MARKET REVENUE

TABLE 19 GLOBAL SALES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 20 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)

FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)

REGIONAL MARKETS BY DISEASE TYPE

PARKINSON'S DISEASE

TABLE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASE BY REGION, 2010-2017 ($ MILLIONS)

MULTIPLE SYSTEM ATROPHY

TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 14 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, 2010-2017 ($ MILLIONS)

PROGRESSIVE SUPRANUCLEAR PALSY

TABLE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, 2010-2017 ($ MILLIONS)

HALLERVORDEN-SPATZ DISEASE

TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 16 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, 2010-2017 ($ MILLIONS)

MARKET BY TECHNOLOGY

SMALL MOLECULES

MONOCLONAL ANTIBODIES

OTHERS

Tau Tangling Inhibitors

Biomarkers

Stem Cells

MARKET OVERVIEW

MARKET REVENUE

TABLE 25 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS)

FIGURE 17 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 26 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)

FIGURE 18 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)

INDUSTRY STRUCTURE

LEADING MANUFACTURERS OF DRUGS USED TO TREAT PARKINSON'S DISEASE

TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PARKINSON'S DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT PARKINSON'S DISEASE

TABLE 28 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASE, 2011 (%)

FIGURE 19 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASE, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT MULTIPLE SYSTEM

ATROPHY

TABLE 29 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT MULTIPLE SYSTEM ATROPHY

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT MULTIPLE SYSTEM ATROPHY

TABLE 30 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)

FIGURE 20 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY

TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY

TABLE 32 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)

FIGURE 21 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT HALLERVORDEN-SPATZ DISEASE

TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HALLERVORDEN-SPATZ DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT HALLERVORDEN-SPATZ DISEASE

TABLE 34 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)

FIGURE 22 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)

CHAPTER 8 PATENT ANALYSIS

PATENTS ISSUED BY YEAR

TABLE 35 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.)

FIGURE 23 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.)

FIGURE 24 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%)

PATENTS BY DISEASE CATEGORY

TABLE 36 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)

FIGURE 25 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%)

PATENTS BY DISEASE TYPE

SYNDROMES OF DEMENTIA

TABLE 37 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012 (NO.)

FIGURE 26 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.)

MOVEMENT DISORDER SYNDROMES

TABLE 38 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)

FIGURE 27 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)

PATENTS BY COUNTRY

SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA)

TABLE 39 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

FIGURE 28 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

TABLE 40 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (%)

MOVEMENT DISORDER SYNDROMES

TABLE 41 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

FIGURE 29 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

TABLE 42 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (%)

PATENTS BY COMPANY

SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA)

TABLE 43 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.)

MOVEMENT DISORDER SYNDROMES

TABLE 44 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY COMPANY, 2010-MARCH 2012 (NO.)

CHAPTER 9 CURRENT SITUATION

MARKET TRENDS

SYNDROMES OF DEMENTIA

Market Drivers

MOVEMENT DISORDER SYNDROMES

Market Drivers

OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS

OTHER FACTORS AFFECTING THE MARKET

COLLABORATIONS/MERGERS AND ACQUISITIONS

CHAPTER 10 COMPANY PROFILES

ABBOTT LABORATORIES

ABLYNX NV

ACCERA INC.

ACORDA THERAPEUTICS INC.

ACTAVIS ELIZABETH

AFFIRIS AG

ALLIANCE PHARMA PLC

ALLON THERAPEUTICS INC.

ALPHAPHARM

ALZHYME LTD.

AMERICAN REGENT INC.

APOTEX INC.

APOTHECA INC.

ASTELLAS PHARMA INC.

ASTRAZENECA GMBH

AUROBINDO PHARMA LTD.

BAXTER INTERNATIONAL INC.

BELLUS HEALTH INC.

BOEHRINGER INGELHEIM LTD.

BRISTOL-MYERS SQUIBB

BRYANT RANCH PREPACK

CADILA HEALTHCARE LTD.

CARACO PHARMACEUTICAL LABORATORIES

CARDINAL HEALTH

CELLZOME AG

CIPLA LTD.

COGNITION THERAPEUTICS INC.

COLUCID PHARMACEUTICALS INC.

COMENTIS INC.

CORTEX PHARMACEUTICALS

CYTOS BIOTECHNOLOGY AG

DAIICHI SANKYO CO. LTD.

DR. REDDY'S LABORATORIES LTD.

EISAI CO. LTD.

ELAN PHARMA INTERNATIONAL LTD.

ELI LILLY AND CO.

ENDO PHARMACEUTICALS INC.

ENVIVO PHARMACEUTICALS

EVOTEC AG

EPITOMICS INC.

EXONHIT THERAPEUTICS SA

FOREST LABORATORIES INC.

GLAXOSMITHKLINE PLC

GLENMARK GENERICS LTD.

H. LUNDBECK A/S

HAMELN PHARMACEUTICALS LTD.

HELICON THERAPEUTICS INC.

HOSPIRA INC.

INTELLECT NEUROSCIENCES INC.

INTRA-CELLULAR THERAPIES INC.

JAZZ PHARMACEUTICALS PLC

MAJOR PHARMACEUTICALS

MEDIVATION INC.

MEMORY PHARMACEUTICALS CORP.

MERCK SERONO

MERCK SHARP & DOHME LTD.

MERZ PHARMA GMBH & CO KGAA

MITHRIDION INC.

MYLAN PHARMACEUTICALS

NEUREN PHARMACEUTICALS LTD.

NEURO-HITECH INC.

NEUROPTIX CORP.

NEUROSEARCH A/S

NEWRON PHARMACEUTICALS SPA

NOSCIRA SA

NOVARTIS AG

NYMOX PHARMACEUTICAL CORP.

ORCHID CHEMICALS & PHARMACEUTICALS LTD.

ORION CORP.

ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.

PAR PHARMACEUTICALS

PERRIGO CO.

PFIZER INC.

PHARNEXT

PHYSICIANS TOTAL CARE INC.

PLIVA HRVATSKA D.O.O.

PRASCO LABORATORIES

RANBAXY LABORATORIES LTD.

ROCHE HOLDING LTD.

ROXANE LABORATORIES INC.

SANDOZ INTERNATIONAL GMBH

SANOFI

SANTHERA PHARMACEUTICALS

SHIONOGI & CO.

STADA ARZNEIMITTEL AG

SUN PHARMA

TAJ PHARMACEUTICALS LTD.

TAKEDA PHARMACEUTICAL CO. LTD.

TERCICA INC.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

TORRENT PHARMA

UCB SA

UDL LABORATORIES

UPSHER-SMITH LABORATORIES

VALEANT PHARMACEUTICALS

VERNALIS PLC

WATSON PHARMACEUTICALS INC.

WEST-WARD PHARMACEUTICAL

CHAPTER 11 APPENDIX I: ABBREVIATIONS

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.